{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T04:11:20Z","timestamp":1789186280010,"version":"build-2803163510"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T00:00:00Z","timestamp":1789171200000},"content-version":"vor","delay-in-days":57,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"DOI":"10.1186\/s12872-026-06267-w","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T11:47:49Z","timestamp":1784288869000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world study of finerenone in patients with heart failure with preserved ejection fraction in Spain"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-4642-6719","authenticated-orcid":false,"given":"Ana","family":"Lamilla \u00c1lvarez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Ripoll Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sof\u00eda","family":"Russo Botero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-2577-1079","authenticated-orcid":false,"given":"Azucena","family":"L\u00f3pez \u00c1lvarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Muela Molinero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"F\u00e1cila Rubio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Garc\u00eda Lamigueiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa Esther","family":"Rodr\u00edguez \u00c1vila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Mar\u00eda","family":"Fern\u00e1ndez Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Bea Granell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Garc\u00eda Escriv\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"P\u00e9rez Silvestre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,17]]},"reference":[{"key":"6267_CR1","doi-asserted-by":"publisher","first-page":"e14","DOI":"10.15420\/cfr.2023.03","volume":"9","author":"CJ Kapelios","year":"2023","unstructured":"Kapelios CJ, Shahim B, Lund LH, Savarese G, Epidemiology. Clinical Characteristics and Cause-specific Outcomes in Heart Failure with Preserved Ejection Fraction. Card Fail Rev. 2023;9:e14. https:\/\/doi.org\/10.15420\/cfr.2023.03.","journal-title":"Card Fail Rev"},{"issue":"1","key":"6267_CR2","doi-asserted-by":"publisher","first-page":"xvag026","DOI":"10.1093\/eschf\/xvag026","volume":"13","author":"K Irlik","year":"2026","unstructured":"Irlik K, Pia\u015bnik J, Hendel M, Faron U, Lip GYH, Nabrdalik K, Prokopidis K. Mortality and heart failure hospitalizations in heart failure with preserved ejection fraction compared to heart failure with reduced ejection fraction: a systematic review and meta-analysis. ESC Heart Fail. 2026;13(1):xvag026. https:\/\/doi.org\/10.1093\/eschf\/xvag026.","journal-title":"ESC Heart Fail"},{"key":"6267_CR3","doi-asserted-by":"publisher","first-page":"132304","DOI":"10.1016\/j.ijcard.2024.132304","volume":"412","author":"A Abdin","year":"2024","unstructured":"Abdin A, B\u00f6hm M, Shahim B, Karlstr\u00f6m P, Kulenthiran S, Skouri H, Lund LH. Heart failure with preserved ejection fraction epidemiology, pathophysiology, diagnosis and treatment strategies. Int J Cardiol. 2024;412:132304. https:\/\/doi.org\/10.1016\/j.ijcard.2024.132304.","journal-title":"Int J Cardiol"},{"issue":"36","key":"6267_CR4","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, B\u00f6hm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599\u2013726. https:\/\/doi.org\/10.1093\/eurheartj\/ehab368.","journal-title":"Eur Heart J"},{"issue":"16","key":"6267_CR5","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","volume":"385","author":"SD Anker","year":"2021","unstructured":"Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, B\u00f6hm M, et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med. 2021;385(16):1451\u201361. https:\/\/doi.org\/10.1056\/NEJMoa2107038.","journal-title":"N Engl J Med"},{"issue":"12","key":"6267_CR6","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","volume":"387","author":"SD Solomon","year":"2022","unstructured":"Solomon SD, McMurray JJV, Claggett B, de Boer RA, DeMets D, Hernandez AF, et al. Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. N Engl J Med. 2022;387(12):1089\u201398. https:\/\/doi.org\/10.1056\/NEJMoa2206286.","journal-title":"N Engl J Med"},{"issue":"37","key":"6267_CR7","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","volume":"44","author":"TA McDonagh","year":"2023","unstructured":"McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, B\u00f6hm M, et al. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2023;44(37):3627\u201339. https:\/\/doi.org\/10.1093\/eurheartj\/ehad195.","journal-title":"Eur Heart J"},{"issue":"5","key":"6267_CR8","doi-asserted-by":"publisher","first-page":"370","DOI":"10.3390\/jpm11050370","volume":"11","author":"C Binder","year":"2021","unstructured":"Binder C, Poglitsch M, Duca F, Rettl R, Dachs TM, Dalos D, et al. Renin Feedback Is an Independent Predictor of Outcome in HFpEF. J Pers Med. 2021;11(5):370. https:\/\/doi.org\/10.3390\/jpm11050370.","journal-title":"J Pers Med"},{"issue":"16","key":"6267_CR9","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1056\/NEJMoa2407107","volume":"391","author":"SD Solomon","year":"2024","unstructured":"Solomon SD, McMurray JJV, Vaduganathan M, Claggett BL, Jhund PS, Desai AS, et al. Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. N Engl J Med. 2024;391(16):1475\u201385. https:\/\/doi.org\/10.1056\/NEJMoa2407107.","journal-title":"N Engl J Med"},{"issue":"6","key":"6267_CR10","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","volume":"43","author":"R Agarwal","year":"2022","unstructured":"Agarwal R, Filippatos G, Pitt B, Anker SD, Rossing P, Joseph A, et al. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J. 2022;43(6):474\u201384. https:\/\/doi.org\/10.1093\/eurheartj\/ehab777.","journal-title":"Eur Heart J"},{"issue":"12","key":"6267_CR11","doi-asserted-by":"publisher","first-page":"3758","DOI":"10.1038\/s41591-024-03264-4","volume":"30","author":"M Vaduganathan","year":"2024","unstructured":"Vaduganathan M, Filippatos G, Claggett BL, Desai AS, Jhund PS, Henderson A, et al. Finerenone in heart failure and chronic kidney disease with type 2 diabetes: FINE-HEART pooled analysis of cardiovascular, kidney and mortality outcomes. Nat Med. 2024;30(12):3758\u201364. https:\/\/doi.org\/10.1038\/s41591-024-03264-4.","journal-title":"Nat Med"},{"key":"6267_CR12","unstructured":"Committee for Medicinal Products for Human Use (CHMP) European Medicines Agency. Kerendia finerenone. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/smop\/chmp-post-authorisation-summary-positive-opinion-kerendia-ema-x-0000248026_en.pdf"},{"issue":"2","key":"6267_CR13","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.jjcc.2023.10.006","volume":"83","author":"T Pol","year":"2024","unstructured":"Pol T, Karlstr\u00f6m P, Lund LH. Heart failure registries - Future directions. J Cardiol. 2024;83(2):84\u201390. https:\/\/doi.org\/10.1016\/j.jjcc.2023.10.006.","journal-title":"J Cardiol"},{"issue":"1","key":"6267_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.medcli.2020.05.059","volume":"157","author":"JC Trull\u00e0s","year":"2021","unstructured":"Trull\u00e0s JC, P\u00e9rez-Calvo JI, Conde-Martel A, Ll\u00e0cer Iborra P, Su\u00e1rez Pedreira I, Ormaechea G, et al. Epidemiology of heart failure with preserved ejection fraction: Results from the RICA Registry. Med Clin (Barc). 2021;157(1):1\u20139. https:\/\/doi.org\/10.1016\/j.medcli.2020.05.059.","journal-title":"Med Clin (Barc)"},{"issue":"17","key":"6267_CR15","doi-asserted-by":"publisher","first-page":"5199","DOI":"10.3390\/jcm11175199","volume":"11","author":"C Escobar","year":"2022","unstructured":"Escobar C, Palacios B, Varela L, Guti\u00e9rrez M, Duong M, Chen H, et al. Prevalence, Characteristics, Management and Outcomes of Patients with Heart Failure with Preserved, Mildly Reduced, and Reduced Ejection Fraction in Spain. J Clin Med. 2022;11(17):5199. https:\/\/doi.org\/10.3390\/jcm11175199.","journal-title":"J Clin Med"},{"issue":"23","key":"6267_CR16","doi-asserted-by":"publisher","first-page":"11584","DOI":"10.3390\/ijms262311584","volume":"26","author":"M L\u00f3pez-Mart\u00ednez","year":"2025","unstructured":"L\u00f3pez-Mart\u00ednez M, Le\u00f3n-Rom\u00e1n J, Su\u00e1rez E, Nu\u00f1ez-Delgado S, Antonieta Azancot M, Zamora-Carrillo JI, et al. Real-World Impact of Finerenone on Albuminuria in Patients with Diabetes and CKD. Int J Mol Sci. 2025;26(23):11584. https:\/\/doi.org\/10.3390\/ijms262311584.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"6267_CR17","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1007\/s13340-025-00839-5","volume":"16","author":"Y Yamao","year":"2025","unstructured":"Yamao Y, Ota M, Kanasaki K. Real-world use of finerenone in diabetic kidney disease: eGFR slope analysis with exploratory data on prior MRA use. Diabetol Int. 2025;16(4):717\u201325. https:\/\/doi.org\/10.1007\/s13340-025-00839-5.","journal-title":"Diabetol Int"},{"issue":"13","key":"6267_CR18","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.3390\/diagnostics14131357","volume":"14","author":"M Hanouneh","year":"2024","unstructured":"Hanouneh M, Le D, Jaar BG, Tamargo C, Cervantes CE. Real-Life Experience on the Effect of SGLT2 Inhibitors vs. Finerenone vs. Combination on Albuminuria in Chronic Kidney Disease. Diagnostics (Basel). 2024;14(13):1357. https:\/\/doi.org\/10.3390\/diagnostics14131357.","journal-title":"Diagnostics (Basel)"},{"issue":"1","key":"6267_CR19","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s40801-021-00277-0","volume":"9","author":"W Li","year":"2022","unstructured":"Li W, Katamreddy A, Kataria R, Myerson ML, Taub CC. Sodium-Glucose Cotransporter-2 Inhibitor Use is Associated with a Reduced Risk of Heart Failure Hospitalization in Patients with Heart Failure with Preserved Ejection Fraction and Type 2 Diabetes Mellitus: A Real-World Study on a Diverse Urban Population. Drugs Real World Outcomes. 2022;9(1):53\u201362. https:\/\/doi.org\/10.1007\/s40801-021-00277-0.","journal-title":"Drugs Real World Outcomes"},{"issue":"6","key":"6267_CR20","doi-asserted-by":"publisher","first-page":"4219","DOI":"10.1002\/ehf2.15424","volume":"12","author":"K Hellenkamp","year":"2025","unstructured":"Hellenkamp K, Kaebe S, Valentova M, von Haehling S, Delistefani F, Gollisch K, et al. Finerenone in diabetic chronic kidney disease-Real-world insights including patients with HFpEF or HFmrEF. ESC Heart Fail. 2025;12(6):4219\u201329. https:\/\/doi.org\/10.1002\/ehf2.15424.","journal-title":"ESC Heart Fail"},{"issue":"12","key":"6267_CR21","doi-asserted-by":"publisher","first-page":"2788","DOI":"10.1002\/ejhf.70034","volume":"27","author":"JW Ostrominski","year":"2025","unstructured":"Ostrominski JW, Claggett BL, Desai AS, Jhund PS, Lam CSP, Senni M, et al. Finerenone according to insulin resistance in heart failure: Insights from the FINEARTS-HF trial. Eur J Heart Fail. 2025;27(12):2788\u201399. https:\/\/doi.org\/10.1002\/ejhf.70034.","journal-title":"Eur J Heart Fail"},{"issue":"7","key":"6267_CR22","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1002\/ejhf.3649","volume":"27","author":"JH Butt","year":"2025","unstructured":"Butt JH, Jhund PS, Henderson AD, Claggett BL, Desai AS, Lam CSP, et al. Finerenone, glycaemic status, and heart failure with mildly reduced or preserved ejection fraction: A prespecified analysis of the FINEARTS-HF trial. Eur J Heart Fail. 2025;27(7):1326\u201341. https:\/\/doi.org\/10.1002\/ejhf.3649.","journal-title":"Eur J Heart Fail"},{"key":"6267_CR23","doi-asserted-by":"publisher","unstructured":"Mc Causland FR, Chatur S, Vaduganathan M, Claggett BL, Kulac IJ, Desai AS, et al. Finerenone and cardiovascular outcomes according to baseline kidney function in patients with heart failure: The FINEARTS-HF Trial. JACC Heart Fail. 2025;14(5):102778. https:\/\/doi.org\/10.1016\/j.jchf.2025.102778","DOI":"10.1016\/j.jchf.2025.102778"},{"key":"6267_CR24","doi-asserted-by":"publisher","unstructured":"Chimura M, Henderson AD, Jhund PS, Claggett BL, Desai AS, Filippatos G et al. Efficacy and safety of the kidney function-based finerenone dosing strategy used in FINEARTS-HF. JACC Heart Fail. 2026;14(6):102938. Epub ahead of print. https:\/\/doi.org\/10.1016\/j.jchf.2026.102938","DOI":"10.1016\/j.jchf.2026.102938"},{"issue":"2","key":"6267_CR25","doi-asserted-by":"publisher","first-page":"251","DOI":"10.2215\/CJN.0000000849","volume":"21","author":"FR Mc Causland","year":"2026","unstructured":"Mc Causland FR, Heerspink HJL, Vaduganathan M, Claggett BL, Desai AS, Jhund PS, et al. Finerenone and eGFR Slope across Different Levels of Baseline Albuminuria and eGFR: Insights from FINEARTS-HF. Clin J Am Soc Nephrol. 2026;21(2):251\u201360. https:\/\/doi.org\/10.2215\/CJN.0000000849.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"6267_CR26","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.jacc.2022.10.028","volume":"81","author":"MS Khan","year":"2023","unstructured":"Khan MS, Shahid I, Anker SD, Fonarow GC, Fudim M, Hall ME, et al. Albuminuria and Heart Failure: JACC State-of-the-Art Review. J Am Coll Cardiol. 2023;81(3):270\u201382. https:\/\/doi.org\/10.1016\/j.jacc.2022.10.028.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"6267_CR27","doi-asserted-by":"publisher","first-page":"102440","DOI":"10.1016\/j.jchf.2025.03.007","volume":"14","author":"JW Ostrominski","year":"2026","unstructured":"Ostrominski JW, Vaduganathan M, Claggett BL, Desai AS, Jhund PS, Lam CSP, et al. Finerenone and NYHA Functional Class in Heart Failure: The FINEARTS-HF Trial. JACC Heart Fail. 2026;14(1):102440. https:\/\/doi.org\/10.1016\/j.jchf.2025.03.007.","journal-title":"JACC Heart Fail"},{"issue":"4","key":"6267_CR28","doi-asserted-by":"publisher","first-page":"3163","DOI":"10.1002\/ehf2.15260","volume":"12","author":"GL Alonso Salinas","year":"2025","unstructured":"Alonso Salinas GL, Mart\u00ednez Le\u00f3n A, Aguiar Cano D, Esteban-Fern\u00e1ndez A, Vi\u00e9itez Fl\u00f3rez JM, Del Prado D\u00edaz S, et al. Clinical utility and safety of finerenone in patients with heart failure: Rationale and design of FINE registry. ESC Heart Fail. 2025;12(4):3163\u201372. https:\/\/doi.org\/10.1002\/ehf2.15260.","journal-title":"ESC Heart Fail"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12872-026-06267-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-026-06267-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-026-06267-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T03:56:56Z","timestamp":1789185416000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12872-026-06267-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,17]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["6267"],"URL":"https:\/\/doi.org\/10.1186\/s12872-026-06267-w","relation":{},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,17]]},"assertion":[{"value":"22 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was carried out in accordance with the ethical principles of the Declaration of Helsinki and the regulations in force. The study was approved by the Research Ethics Committee for Medicinal Products of\n                      Fundaci\u00f3n de Investigaci\u00f3n del Hospital General Universitario de Valencia\n                      (Valencia, Spain). The committee approved the exemption of informed consent, as it was an observational and retrospective study, without any intervention on the patient.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"791"}}